lenalidomide sandoz 20 mg
sandoz - københavn - lenalidomid - kapsel, hard - 20 mg
lenalidomide sandoz 25 mg
sandoz - københavn - lenalidomid - kapsel, hard - 25 mg
lenalidomid zentiva 20 mg
zentiva k.s. - lenalidomid - kapsel, hard - 20 mg
lenalidomid zentiva 2.5 mg
zentiva k.s. - lenalidomid - kapsel, hard - 2.5 mg
lenalidomid zentiva 5 mg
zentiva k.s. - lenalidomid - kapsel, hard - 5 mg
lenalidomid zentiva 7.5 mg
zentiva k.s. - lenalidomid - kapsel, hard - 7.5 mg
lenalidomid zentiva 10 mg
zentiva k.s. - lenalidomid - kapsel, hard - 10 mg
lenalidomid zentiva 15 mg
zentiva k.s. - lenalidomid - kapsel, hard - 15 mg
lenalidomid zentiva 25 mg
zentiva k.s. - lenalidomid - kapsel, hard - 25 mg
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - multippelt myelom - antineoplastiske midler - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.